NanoEcho (NANECH) Q1 2025 earnings summary

Executive summary

• Achieved key milestone with successful completion of clinical dose confirmation study, establishing optimal nanoparticle dose and imaging interval for rectal cancer diagnostics.

• Raised capital through a rights issue, enabling continued clinical development and optimization of diagnostic system.

• Published health economic analysis in PharmacoEconomics, supporting cost-effectiveness and patient benefit of NanoEcho's method.

• Entered strategic partnership to optimize AI-based diagnostic algorithm for clinical use.

• Strengthened validation of core nanoparticle technology through positive phase III MRI study results in prostate cancer.

Financial highlights

• Net sales for Q1 2025 were 0 TSEK, consistent with clinical phase status; operating income was -4,310 TSEK compared to -3,979 TSEK last year.

• Net loss after tax was -5,302 TSEK, widening from -3,978 TSEK year-over-year.

• Cash flow from operating activities was -6,047 TSEK, down from -3,880 TSEK in Q1 2024.

• Cash and cash equivalents at period end were 12,398 TSEK, up from 8,918 TSEK last year.

• Equity increased to 24,897 TSEK (14,518 TSEK in Q1 2024), with a solid equity ratio of 87%.

Outlook and guidance

• Focus remains on clinical optimization and regulatory preparation, with plans to seek market approval in 2027.

• Ongoing development of AI-driven diagnostic algorithm and further clinical studies to establish clinical benefit.

• Company highlights economic and geopolitical uncertainty as a risk to financing and market conditions.